These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 32798587

  • 1. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
    Li X, Wei Y, Wei X.
    Cancer Lett; 2020 Oct 28; 491():146-161. PubMed ID: 32798587
    [Abstract] [Full Text] [Related]

  • 2. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y, Peng X, Li H, Jiao W, Peng X, Shao J, Xu Y, Wang R, Wang W, Kong D.
    Recent Pat Anticancer Drug Discov; 2021 Oct 28; 16(3):350-362. PubMed ID: 33655847
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH, Määttä J, Linder A, Sterbova S, Ohlsson C, Damber JE, Widmark A, Persson E.
    Prostate; 2021 Jun 28; 81(8):452-462. PubMed ID: 33822400
    [Abstract] [Full Text] [Related]

  • 4. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
    Li C, Chen C, An Q, Yang T, Sang Z, Yang Y, Ju Y, Tong A, Luo Y.
    Eur J Med Chem; 2019 Jan 15; 162():543-554. PubMed ID: 30472602
    [Abstract] [Full Text] [Related]

  • 5. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
    Han D, Yu T, Dong N, Wang B, Sun F, Jiang D.
    J Exp Clin Cancer Res; 2019 Jul 05; 38(1):289. PubMed ID: 31277685
    [Abstract] [Full Text] [Related]

  • 6. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
    Löcken H, Clamor C, Müller K.
    J Nat Prod; 2018 Jul 27; 81(7):1636-1644. PubMed ID: 30003778
    [Abstract] [Full Text] [Related]

  • 7. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
    Sun X, Li B, Xie B, Xu Z, Chang G, Tao Y, Zhang Y, Chang S, Wang Y, Yu D, Xie Y, Li T, Wang H, Chen G, Hu L, Hou J, Zhang Y, Xiao W, Gao L, Shi J, Zhu W.
    Cell Death Dis; 2017 Oct 12; 8(10):e3111. PubMed ID: 29022919
    [Abstract] [Full Text] [Related]

  • 8. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
    Shao Z, Wang H, Ren H, Sun Y, Chen X.
    Molecules; 2023 Jul 27; 28(15):. PubMed ID: 37570646
    [Abstract] [Full Text] [Related]

  • 9. Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
    Kaneko N, Kita A, Yamanaka K, Mori M.
    Leuk Res; 2013 Sep 27; 37(9):1156-61. PubMed ID: 23746965
    [Abstract] [Full Text] [Related]

  • 10. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
    Hubbard JM, Grothey A.
    Drugs; 2017 Jul 27; 77(10):1091-1103. PubMed ID: 28573435
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
    Zuo D, Shogren KL, Zang J, Jewison DE, Waletzki BE, Miller AL, Okuno SH, Cai Z, Yaszemski MJ, Maran A.
    J Exp Clin Cancer Res; 2018 Oct 04; 37(1):244. PubMed ID: 30286779
    [Abstract] [Full Text] [Related]

  • 12. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
    Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Rosenblum MG.
    Biochem Pharmacol; 2010 Nov 01; 80(9):1335-42. PubMed ID: 20654581
    [Abstract] [Full Text] [Related]

  • 13. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
    Wang YT, Tang F, Hu X, Zheng CX, Gong TJ, Zhou Y, Luo Y, Min L.
    IUBMB Life; 2020 Oct 01; 72(10):2146-2153. PubMed ID: 33448097
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
    Chang AY, Hsu E, Patel J, Li Y, Zhang M, Iguchi H, Rogoff HA.
    Mol Cancer Res; 2019 Jul 01; 17(7):1429-1434. PubMed ID: 31043490
    [Abstract] [Full Text] [Related]

  • 15. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
    Bose M, Sanders A, Handa A, Vora A, Cardona MR, Brouwer C, Mukherjee P.
    Sci Rep; 2024 Feb 07; 14(1):3178. PubMed ID: 38326371
    [Abstract] [Full Text] [Related]

  • 16. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
    Froeling FEM, Swamynathan MM, Deschênes A, Chio IIC, Brosnan E, Yao MA, Alagesan P, Lucito M, Li J, Chang AY, Trotman LC, Belleau P, Park Y, Rogoff HA, Watson JD, Tuveson DA.
    Clin Cancer Res; 2019 Dec 01; 25(23):7162-7174. PubMed ID: 31527169
    [Abstract] [Full Text] [Related]

  • 17. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.
    Mai Y, Yu JJ, Bartholdy B, Xu-Monette ZY, Knapp EE, Yuan F, Chen H, Ding BB, Yao Z, Das B, Zou Y, Young KH, Parekh S, Ye BH.
    Blood; 2016 Dec 15; 128(24):2797-2807. PubMed ID: 27737889
    [Abstract] [Full Text] [Related]

  • 18. Effect of napabucasin and doxorubicin via the Jak2/Stat3 signaling pathway in suppressing the proliferation of neuroblastoma cells.
    Ünlü İ, Tuncer MC, Özdemir İ.
    Acta Cir Bras; 2024 Dec 15; 39():e396624. PubMed ID: 39356934
    [Abstract] [Full Text] [Related]

  • 19. TAK1 is a druggable kinase for diffuse large B-cell lymphoma.
    Wu Y, Yang R, Ming Y, Xu Y, Chen H, Yao M, Chen X, Mao R, Fan Y.
    Cell Biochem Funct; 2019 Apr 15; 37(3):153-160. PubMed ID: 30907011
    [Abstract] [Full Text] [Related]

  • 20. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism.
    Leijten NM, Bakker P, Spaink HP, den Hertog J, Lemeer S.
    Mol Cell Proteomics; 2021 Apr 15; 20():100033. PubMed ID: 33594990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.